Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
SYXYMCwNyu2YguRH
